The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Her2-positive Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) ECOG Performance Status 0-1. 2) Adequate hepatic, renal, and bone marrow function. 3)Not pregnant and not nursing.

You may not be eligible for this study if the following are true:

  • 1) Patients with known active and/or untreated Hepatitis B or Hepatitis C or chronic liver disease are ineligible. 2) History of any prior (ipsi- or contralateral) invasive breast cancer within 3 years of registration. 3) Evidence of recurrent disease following preoperative therapy and surgery. 4) History of exposure to the following cumulative doses of anthracyclines: Doxorubicin > 240 mg/m2; Epirubicin or Liposomal Doxorubicin-Hydrochloride (Myocet┬«) > 480 mg/m2. For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m2.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.